Literature DB >> 3244624

The measurement of warfarin enantiomers in serum using coupled achiral/chiral, high-performance liquid chromatography (HPLC).

Y Q Chu1, I W Wainer.   

Abstract

An assay for the serum concentration of the enantiomers of warfarin, R-warfarin and S-warfarin, has been developed using a bovine serum albumin chiral stationary phase (BSA-CSP) coupled to a Pinkerton internal-surface reverse-phase (ISRP) achiral column. The ISRP column is used to separate R,S-warfarin from the serum components and warfarin metabolites and to quantitate the total R,S-warfarin concentration. The eluent containing R,S-warfarin is then selectively transferred to the BSA-CSP, where the enantiomers are stereochemically resolved (alpha = 1.19) and the enantiomeric composition is determined. This system is sensitive and accurate, does not require extensive precolumn manipulations, and can be automated for use in large-scale clinical studies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3244624     DOI: 10.1023/a:1015991324316

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  Interaction of the enantiomers of warfarin with human serum albumin, peptides and amino acids [proceedings].

Authors:  J H Miller; G A Smail
Journal:  J Pharm Pharmacol       Date:  1977-12       Impact factor: 3.765

2.  Studies on the optical enantiomorphs of warfarin in man.

Authors:  R A O'Reilly
Journal:  Clin Pharmacol Ther       Date:  1974-08       Impact factor: 6.875

3.  Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man.

Authors:  A Breckenridge; M Orme; H Wesseling; R J Lewis; R Gibbons
Journal:  Clin Pharmacol Ther       Date:  1974-04       Impact factor: 6.875

4.  Stereospecific high-performance liquid chromatographic analysis of warfarin in plasma.

Authors:  C Banfield; M Rowland
Journal:  J Pharm Sci       Date:  1983-08       Impact factor: 3.534

5.  Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man.

Authors:  D S Hewick; J McEwen
Journal:  J Pharm Pharmacol       Date:  1973-06       Impact factor: 3.765

6.  A stable isotope assay for pseudoracemic warfarin from human plasma samples.

Authors:  W N Howald; E D Bush; W F Trager; R A O"Reilly; C H Motley
Journal:  Biomed Mass Spectrom       Date:  1980-01

7.  Kinetics of R andS warfarin enantiomers.

Authors:  C Hignite; J Uetrecht; C Tschanz; D Azarnoff
Journal:  Clin Pharmacol Ther       Date:  1980-07       Impact factor: 6.875

8.  Warfarin enantiomer disposition: determination by stereoselective radioimmunoassay.

Authors:  C E Cook; N H Ballentine; T B Seltzman; C R Tallent
Journal:  J Pharmacol Exp Ther       Date:  1979-09       Impact factor: 4.030

9.  Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine.

Authors:  C Banfield; M Rowland
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

  9 in total
  3 in total

Review 1.  High performance affinity chromatography and related separation methods for the analysis of biological and pharmaceutical agents.

Authors:  Chenhua Zhang; Elliott Rodriguez; Cong Bi; Xiwei Zheng; Doddavenkatana Suresh; Kyungah Suh; Zhao Li; Fawzi Elsebaei; David S Hage
Journal:  Analyst       Date:  2018-01-15       Impact factor: 4.616

2.  Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin.

Authors:  E Chan; A J McLachlan; M Pegg; A D MacKay; R B Cole; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

3.  Column-switching high-performance liquid chromatography for on-line simultaneous determination and resolution of enantiomers of verapamil and its metabolites.

Authors:  Y Oda; N Asakawa; T Kajima; Y Yoshida; T Sato
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.